Who should I contact about this recall?

Contact Becton Dickinson & Co. directly, or the distributor/pharmacy that supplied the product, to confirm whether your specific lot or unit is affected. Argus HQ aggregates the public FDA recall record and is not the recalling firm.

Has Becton Dickinson & Co. had other FDA recalls or enforcement actions?

Yes. Argus HQ has recorded 96 total FDA actions tied to Becton Dickinson & Co., including 96 recalls and 0 warning letters.

FDA Recall Database: Class II Recall: BD BBL Sensi Disc Minocycline - 30 ug,… by Becton Dickinson & Co.

Here's the summary: FDA classified a recall by Becton Dickinson & Co. as Class II, reported 20240214. The affected product is BD BBL Sensi Disc Minocycline - 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231250 and 231251¿ (recall number Z-1034-2024). Reason for recall: There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.. Status: Ongoing.

Key facts

Recalling firm	Becton Dickinson & Co.
Manufacturer	Not disclosed in the FDA record.
Brand name	Not disclosed in the FDA record.
Product description	BD BBL Sensi Disc Minocycline - 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231250 and 231251¿
Classification	Class II
Recall number	Z-1034-2024
Report date	Not disclosed in the FDA record.
Status	Ongoing
Reason for recall	There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

What consumers should do

Facilities, clinicians, and consumers holding an affected unit or lot of BD BBL Sensi Disc Minocycline - 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231250 and 231251¿ should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Becton Dickinson & Co.. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Becton Dickinson & Co. should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Becton Dickinson & Co. directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.

What this classification means

A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.

Becton Dickinson & Company’s FDA history

Argus HQ has recorded 96 total FDA actions tied to Becton Dickinson & Company: 0 warning letters, 96 recalls, 0 approval records, and 0 Form 483 inspection citations.

Frequently asked questions

Why was BD BBL Sensi Disc Minocycline - 30 ug, used for semi-quanti recalled?: FDA's recall record states the reason as: There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.
Who should I contact about this recall?: Contact Becton Dickinson & Co. directly, or the distributor/pharmacy that supplied the product, to confirm whether your specific lot or unit is affected. Argus HQ aggregates the public FDA recall record and is not the recalling firm.
Has Becton Dickinson & Co. had other FDA recalls or enforcement actions?: Yes. Argus HQ has recorded 96 total FDA actions tied to Becton Dickinson & Co., including 96 recalls and 0 warning letters.
What is the FDA recall number for this event?: FDA recall number Z-1034-2024.

Know if this happens again — we'll email you.

Free. No spam, just recall alerts for what you tell us to watch.

Full FDA history for Becton Dickinson & Company

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2024). FDA Recall Database: Class II Recall: BD BBL Sensi Disc Minocycline - 30 ug,… by Becton Dickinson & Co.. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/recall/becton-dickinson-and-z-1034-2024-2024-02-14

MLA

"FDA Recall Database: Class II Recall: BD BBL Sensi Disc Minocycline - 30 ug,… by Becton Dickinson & Co.." Argus HQ Research, Digital Empire Holdings LLC, 2024, argushq.ai/recall/becton-dickinson-and-z-1034-2024-2024-02-14.

Chicago

Argus HQ Research. "FDA Recall Database: Class II Recall: BD BBL Sensi Disc Minocycline - 30 ug,… by Becton Dickinson & Co.." Digital Empire Holdings LLC. Accessed July 24, 2026. https://argushq.ai/recall/becton-dickinson-and-z-1034-2024-2024-02-14.

BibTeX

@misc{argushq_argushq_ai_recall_becton_dickinson_and_z_1034_2024_2024_02_14_2024,
  title = {FDA Recall Database: Class II Recall: BD BBL Sensi Disc Minocycline - 30 ug,… by Becton Dickinson & Co.},
  author = {{Argus HQ Research}},
  year = {2024},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/recall/becton-dickinson-and-z-1034-2024-2024-02-14},
  note = {Accessed: July 24, 2026}
}

Source: FDA.gov — Recalls ↗